Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Revenue Multiple | 1.6x - 1.8x | 1.7x |
| Selected Fwd Revenue Multiple | 1.4x - 1.5x | 1.4x |
| Fair Value | $0.25 - $0.79 | $0.52 |
| Upside | -65.0% - 11.5% | -26.7% |
| Benchmarks | Ticker | Full Ticker |
|---|---|---|
| DexCom, Inc. | DXCM | NasdaqGS:DXCM |
| Neogen Corporation | NEOG | NasdaqGS:NEOG |
| IDEXX Laboratories, Inc. | IDXX | NasdaqGS:IDXX |
| Biomerica, Inc. | BMRA | NasdaqCM:BMRA |
| MedMira Inc. | MMIR.F | PINC:MMIR.F |
| Trinity Biotech plc | TRIB | NasdaqGS:TRIB |
| Select LTM Revenue Multiple | ||||||||
| Benchmark Companies | ||||||||
| DXCM | NEOG | IDXX | BMRA | MMIR.F | TRIB | |||
| NasdaqGS:DXCM | NasdaqGS:NEOG | NasdaqGS:IDXX | NasdaqCM:BMRA | PINC:MMIR.F | NasdaqGS:TRIB | |||
| Historical Revenue Growth | ||||||||
| 5Y CAGR | 22.3% | 17.4% | 10.1% | 0.8% | -4.8% | -10.1% | ||
| 3Y CAGR | 18.1% | 25.4% | 6.6% | -9.1% | -42.3% | -17.7% | ||
| Latest Twelve Months | 11.3% | -2.5% | 6.5% | 5.0% | -32.1% | -17.2% | ||
| Historical EBIT Profit Margin | ||||||||
| 5 Year Average Margin | 14.1% | 12.7% | 27.9% | -81.0% | -343.5% | -4.9% | ||
| Prior Fiscal Year | 16.5% | 12.5% | 30.0% | -135.3% | -449.5% | -21.6% | ||
| Latest Fiscal Year | 14.9% | 8.1% | 30.5% | -117.6% | -623.7% | -28.3% | ||
| Latest Twelve Months | 14.9% | 4.5% | 30.5% | -89.8% | -1307.4% | -17.8% | ||
| Current Trading Multiples | ||||||||
| EV / LTM Revenue | 6.97x | 2.08x | 9.27x | 1.27x | 283.50x | 1.76x | ||
| EV / LTM EBIT | 46.9x | 46.4x | 30.4x | -1.4x | -21.7x | -9.9x | ||
| Price / LTM Sales | 6.97x | 1.24x | 9.10x | 1.74x | 228.22x | 0.22x | ||
| Low | Mid | High | ||||||
| Benchmark EV / LTM Revenue | 1.27x | 6.97x | 283.50x | |||||
| Historical EV / LTM Revenue | 0.84x | 0.97x | 1.76x | |||||
| Selected EV / LTM Revenue | 1.64x | 1.73x | 1.81x | |||||
| (x) LTM Revenue | 59 | 59 | 59 | |||||
| (=) Implied Enterprise Value | 97 | 102 | 107 | |||||
| (-) Non-shareholder Claims * | (91) | (91) | (91) | |||||
| (=) Equity Value | 6 | 11 | 16 | |||||
| (/) Shares Outstanding | 18.6 | 18.6 | 18.6 | |||||
| Implied Value Range | 0.33 | 0.61 | 0.88 | |||||
| FX Rate: USD/USD | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 0.33 | 0.61 | 0.88 | 0.71 | ||||
| Upside / (Downside) | -53.4% | -14.5% | 24.3% | |||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | DXCM | NEOG | IDXX | BMRA | MMIR.F | TRIB | |
| Enterprise Value | 27,994 | 1,886 | 36,117 | 7 | 35 | 104 | |
| (+) Cash & Short Term Investments | 2,579 | 128 | 288 | 3 | 0 | 3 | |
| (+) Investments & Other | 119 | 0 | 31 | 0 | 0 | 0 | |
| (-) Debt | (2,594) | (894) | (987) | (1) | (16) | (94) | |
| (-) Other Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Preferred Stock | 0 | 0 | 0 | 0 | (0) | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 28,098 | 1,120 | 35,450 | 10 | 20 | 13 | |
| (/) Shares Outstanding | 392.1 | 217.0 | 81.0 | 2.5 | 701.7 | 18.6 | |
| Implied Stock Price | 71.66 | 5.16 | 437.44 | 3.88 | 0.03 | 0.71 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.39 | 1.00 | |
| Implied Stock Price (Trading Cur) | 71.66 | 5.16 | 437.44 | 3.88 | 0.02 | 0.71 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.39 | 1.00 | |